Steven Pieper - 29 Jan 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Financial Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
29 Jan 2022
Net transactions value
-$454,284
Form type
4
Filing time
09 Aug 2024, 16:06:56 UTC
Previous filing
05 Jan 2022
Next filing
01 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $7,301 -3,460 -0.21% $2.11* 1,623,452 29 Jan 2022 Direct F1, F2
transaction XERS Common Stock Tax liability $1,582 -750 -0.05% $2.11* 1,622,702 31 Jan 2022 Direct F1, F3
transaction XERS Common Stock Tax liability $13,967 -9,767 -0.6% $1.43* 1,612,935 28 Jul 2022 Direct F1, F4
transaction XERS Common Stock Tax liability $25,835 -23,067 -1.4% $1.12 1,589,868 03 Jan 2023 Direct F1, F5
transaction XERS Common Stock Tax liability $4,523 -3,590 -0.23% $1.26 1,586,278 29 Jan 2023 Direct F1, F6
transaction XERS Common Stock Tax liability $965 -778 -0.05% $1.24 1,585,500 31 Jan 2023 Direct F1, F7
transaction XERS Common Stock Tax liability $25,806 -10,200 -0.64% $2.53 1,575,300 28 Jul 2023 Direct F1, F8
transaction XERS Common Stock Tax liability $51,670 -23,067 -1.5% $2.24 1,552,233 03 Jan 2024 Direct F1, F9
transaction XERS Common Stock Tax liability $11,648 -4,379 -0.28% $2.66 1,547,854 29 Jan 2024 Direct F1, F10
transaction XERS Common Stock Tax liability $272,445 -110,750 -7.2% $2.46 1,437,104 31 Jan 2024 Direct F1, F11
transaction XERS Common Stock Tax liability $38,542 -14,767 -1% $2.61 1,422,337 28 Jul 2024 Direct F1, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction is being reported late due to administrative oversight.
F2 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January, 29, 2022.
F3 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
F4 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of July 28, 2022.
F5 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
F6 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
F7 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
F8 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of July 28, 2023.
F9 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
F10 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
F11 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.
F12 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of July 28, 2024.

Remarks:

Chief Financial Officer